Logo
x

Search

Subscribe Now

Ocugen

Ocugen Reports the US FDA’s Approval of Expanded Access Program for Retinitis Pigmentosa Patients

Ocugen Reports the US FDA’s Approval of Expanded Access Program for Retinitis Pigmentosa Patients

  • August 6, 2024
Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease

Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease

  • May 15, 2024
Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital...

  • April 14, 2023
Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

  • May 24, 2022
PharmaShots Weekly Snapshots (December 27- 31, 2021)

PharmaShots Weekly Snapshots (December 27- 31, 2021)

  • December 31, 2021
Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19

Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19

  • December 31, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.